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ABSTRACT
Introduction: Psoriasis results in expenses to
patients from many cost sources. Psoriasis
treatments may result in considerable time
and traveling costs, yet many studies fail to
account for these costs. The objective of this
study was to evaluate the multidimensional
economic burden of psoriasis to patients.
Methods: The study was based on 232 Finnish
patients with psoriasis or psoriatic arthritis
visiting a tertiary level dermatological clinic
during a 1-year study period between October 1,
2009 and September 30, 2010. The data were
based on a patient questionnaire, clinical data
from the medical records and reimbursement
data from the Finnish Social Insurance
Institution. Item costs were based on true costs
charged from the patients and all time cost
estimates were based on the Human Capital
Approach method.
Results: 199 patients with psoriasis and 33 with
psoriatic arthritis were included in the study.
Total costs were higher for patients receiving
traditional systemic medications or
phototherapy than those not receiving such
treatment. Travel costs and travel time costs
accounted for more than 60% of the costs of
phototherapy. Skin care at home was time
consuming and thus caused significant burden
to patients. The majority of the visit costs arose
from hospital visits and only a small proportion
were attributed to visiting primary health care
providers.
Conclusion: Visit charges and other patient co-
payments were estimated to play a minor role in
the total cost of psoriasis incurred by patients,
while travel costs and lost time comprised the
majority of the costs, which should not be
omitted in future studies regarding costs of
treatments.
Electronic supplementary material The online
version of this article (doi:10.1007/s13555-014-0053-2)
contains supplementary material, which is available to
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INTRODUCTION
Psoriasis is a common chronic inflammatory
disease with a prevalence of 1.5–2.8%
worldwide [1, 2]. Around 6–30% of patients
with psoriasis also have psoriatic arthritis [3–5].
Psoriasis is a lifelong disease thus leading to
considerable burden and expenses [1, 6]. When
assessing the health economic consequences of
a disease, the perspective of patients is
considered important [1, 7].
Psoriasis results in expenses to patients from
many cost sources mainly because of
medications, topical emollients and
balneotherapy [8–12]. Some psoriasis
treatments (mainly phototherapy) are given in
hospitals, usually in as a course of treatment, so
considerable time and traveling costs can be
expected [7, 11, 13]. Studies have estimated that
patients have to spend a lot of time each day in
home care of psoriasis, but the results have wide
variations [11, 12]. Psoriasis also increases the
need for cleaning and laundry, and increases
the need for assistance at home [11].
Psoriasis has no known curative treatment;
therapy aims to reduce symptoms and gain
quality of life. Topical steroids and vitamin D
analogs are shown to be the most commonly
used treatment method [5]. Phototherapy and/
or systemic medications are combined if
necessary [5]. Countries have varying social/
private insurance systems, thus the costs of
medications for the patients varies.
The aim of this study was to evaluate the




The sample was based on patients who had
visited the Department of Dermatology in
Turku University Hospital (TUH) between
October 1, 2009 and September 30, 2010.
They were all diagnosed with moderate to
severe psoriasis or psoriatic arthritis. The
patient sample is described in detail by
Mattila et al. [14]. In the Finnish healthcare
system patients with mild psoriasis are treated
in primary health care settings and only
moderate to severe cases are referred to
tertiary level hospitals for further treatment.
In practice, all psoriatic arthritis patients in
this study sample also had skin symptoms,
which had been the reason for visiting a
dermatological clinic.
Ethical Consideration
The ethical committee of The Hospital
District of Southwest Finland approved the
study. The patients received a written
description of the sampling procedure and
study purpose, as well as the planned use
and storage of the information they were to
provide. This was followed by a description
of the subject’s rights according to the
Helsinki declaration. All procedures followed
were in accordance with the ethical
standards of the responsible committee on
human experimentation (institutional and
national) and with the Helsinki Declaration
of 1975, as revised in 2000 and 2008.
Written informed consent was obtained
from all patients for use of their medical
records being included in the study.
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Questionnaire
The questionnaire collected socio-demographic
background information (e.g., sex, age, home
municipality, number of persons living in the
same household, income level and disease
duration).
To evaluate the use of different medical
services and associated out-of-pocket expenses
and time spent, the subjects were asked the
number of visits they had made to a private or
occupational health care provider, to a tertiary
level hospital and to a health center because of
psoriasis during the study period of 1 year. The
visits to doctors’ office and nurse in each health
care facility were recorded separately. The time
spent, in hours per year, was recorded for each
health service provider. The subjects were asked
to evaluate the out-of-pocket expenses
associated with the different health care
providers. The subjects were also asked to
estimate the distances to each health care
provider in kilometers from their home.
The subjects were asked to report how many
minutes per week they currently spend on
caring for their skin, cleaning and laundry,
and to estimate the time in minutes per week
they would have spent in a hypothetical
situation if they did not have psoriasis. Skin
care, cleaning and laundry time caused by
psoriasis was defined as the difference between
estimated time spent in skin care, cleaning and
laundry with and without psoriasis.
The subjects were asked if they received any
assistance with running errands or household
chores because of psoriasis and respective costs
(in euro per month).
Time Cost
All cost estimates were computed to hours per
year. To estimate the monetary value of the
burden from the time consumed for household
chores, running errands, for skin care and
treatment-related time, the Human Capital
Approach (HCA) was used. The value of an
hour was based on the level of total family
income per persons in the household. The
monthly income levels were computed to an
hour. The same formula was applied to retired
and unemployed respondents.
Clinical Data
Clinical information was collected from the
medical records for the time period that was
covered in the questionnairedata. Outpatient and
phototherapy visits and the days hospitalized
were collected from the hospital records.
Psoriasis area severity index (PASI) and
diagnosis [ICD-1010 (International Statistical
Classification of Diseases and Related Health
Problems)] were collected to classify the severity
and the type of psoriasis. If there were many
PASI values from the same patient, the mean
value for the study period was calculated and
used in the analyses.
Patients were divided into subgroups for
further assessment by type of psoriasis
(psoriatic arthritis and psoriasis) and the
severity of psoriasis according to PASI values.
When analyzing the subgroups with recorded
PASI values (n = 72) patients were divided by
the median value into more severe (PASI [5.5,
n = 37) and less severe psoriasis (PASI B5.5,
n = 35). Patients were categorized to those
who received phototherapy and those who did
not, and to those who were receiving traditional
systemic medications (including methotrexate,
acitretin, and cyclosporine) and to those who
did not (receiving mainly phototherapy and/or
topical therapy). Patients may be included in
more than one group, as combined therapy was
possible.
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Pharmaceuticals
In practice, Finnish patients with psoriasis
receive reimbursements for all their
medications and emollients from the Finnish
Social Insurance Institution (FSII). FSII provided
data on all psoriasis-related medication
including different drugs (biologic, systemic
and topical), supportive drugs (e.g., antifungal
drugs and antihistamines) and self-care
products (e.g., emollients) purchased during
the study period for the patients who had
given consent. This reimbursement policy
applies to all medications, irrespective of who
has prescribed them. All purchase data included
the cost for the patient and the amount
reimbursed as well as the type of medication
purchased. If the out-of-pocket expenses for
medicine and emollients exceed 672 euro
during a calendar year, the exceeding
reimbursement was at a rate of 100% so the
cost maximum was set to 672 euro.
Travel Costs and Time
Travel costs were estimated using the distances
from patients’ home to different health care
providers and the number of visits in each
destination. If the distance to a service provider
was less than 12.5 km, a typical regional bus fee
of 2.5 euro was applied. For distances beyond
12.5 km, 0.20 euro/km derived from FSII
reimbursement rate for traveling cost was used
for costs calculations.
The time patients spent on traveling to
different health service providers was
estimated using the distance to the service
provider from their home municipality and
the number of visits to each provider; register
data were used for TUH visits. An
approximation of 1.5 min per kilometer was
used with an additional fixed amount of 5 min
representing the time needed to park the car or
walk from the bus stop to the hospital. In the
few cases where the estimated travel time to a
service provider and back home exceeded 2.5 h,
it was capped at 2.5 h.
Visit Time
The time spent at different health care providers
was solicited in the questionnaire and used to
evaluate the costs of the time needed for visits.
Due to the significance of time needed for
phototherapy, a separate survey was conducted,
where the actual time needed by 40 patients
with psoriasis attending phototherapy at TUH
was observed. UVB and bath-PUVA therapies
were separately recorded. UVB visits took on
average 16 min and bath-PUVA took 43 min.
Other forms of PUVA treatment than bath-
PUVA were not used. These times were then
used for time–cost calculations of
phototherapy.
Visiting Charges
The charge for an outpatient visit to a tertiary
level hospital in 2009 was 27.40 euro. For a
course of treatment (e.g., phototherapy) the
charge was 7.00 euro per visit. For
appointments that were missed without prior
cancelation, there was a charge of 33.80 euro on
each occasion. For inpatient treatment, the
daily charge to the patient was 32.50 euro.
The combined inpatient and outpatient fees for
a patient to a tertiary level hospital were capped
at 633 euro during a year, as beyond this level,
further visits to hospital are free of charge to the
patient. TUH charges were based on register
data.
A visit to a private specialist was valued at
100 euro per visit and a visit to a private nurse
was valued at 50 per visit. These approximate
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costs were derived from the average charges of
the largest private health service providers. FSII
reimbursed 20.25 euro for a visit to a private
specialist and an average of 8 euro for a visit to a
private nurse. These reimbursements were
deducted from the average charges to compute
the cost to a patient of visiting the private
sector. For visiting the health center the charge
for the patient is 12.80 euro, which is only
claimed for the first three visits. Patients did not
pay a visiting fee when visiting a public health
sector nurse or an occupational health care
provider.
Statistical Analyses
The statistical evaluation of the data was based
on Student’s t test for means and Chi-square test
for proportions. Linear regression models were
used to study how different background factors
affected the variation in treatment cost
estimates. In the analyses all patients with
missing information in any of the analyzed
variables were excluded. All analyses were based
on all patients irrespective of the diagnosis of
psoriasis or psoriatic arthritis.
RESULTS
The patients had relatively low psoriasis severity
(Table 1). The total costs to patients were higher
for those receiving traditional systemic
medications than not receiving systemic
medications (Table 2). Medicine costs, skin
care cost and costs of assistance for household
chores comprised most of the differences
(Table 2). Visit costs were higher for patients
not receiving traditional systemic medications,
mainly because their costs of phototherapy (217
euro, SD 358) were higher (p\0.001) than for
those who received systemic medications (82
euro, SD 228).
Medications and phototherapy formed 18%
of the total economic burden for a patient.








Mean age (years) 62 (12) 55* (13) 57 (13)
Male 53% 56% 54%
PsA patients 15% 12% 14%
Mean PASI (n = 72) 6.3 (2.3) 6.6 (4.7) 6.5 (4.0)
Mean DLQI (n = 36) 10.1 (8.6) 12.8 (7.8) 11.0 (8.3)
Number of total visits 6 (7) 10* (10) 8 (9)
Visit time (h) 8 (29) 8 (19) 8 (23)
Travel time (h) 6 (9) 10* (13) 8 (12)
Travel distance (km) 124 (231) 186 (329) 163 (298)
Skin care time (h) 100 (126) 76 (92) 85 (106)
Described as average or mean annual values (standard deviation in parenthesis)
DLQI dermatology life quality index, PASI psoriasis area severity index
* p\0.05, otherwise non-signiﬁcant
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Phototherapy and biologic medications (527
euro, SD 280, n = 14) were the costliest
therapies for a patient to receive. Travel costs
and travel time costs comprised over 60% of the
costs of phototherapy (Table 3). Patients
receiving phototherapy lived on average 10 km
closer to TUH than those who did not receive
phototherapy (p\0.05).
A majority of the total visit costs incurred by
patients were from visiting TUH and only a
small proportion from visiting all primary
health care providers (Table 4). Patients with
psoriatic arthritis received more phototherapy
and had more visits, thus had higher visiting
costs than patients with psoriasis (Table 4).
Patients with more severe psoriasis (PASI [5.5)
had higher (p\0.05) total visiting costs (673
euro, SD 848) than patients with less severe
psoriasis (PASI B5.5) (359 euro, SD 369).
Patients who received phototherapy had
higher (p\0.001) total visiting costs (673
euro, SD 658) than the patients who did not
receive phototherapy (234 euro, SD 310).
Skin care time (Table 1) was estimated to
correspond to almost half of the total economic
burden to the patient (Table 2). Patients
receiving traditional systemic medications had
higher costs for skin care than those who did
not (Table 2). Sex, age, diagnosis, the severity of
psoriasis or receiving phototherapy did not
have a statistically significant effect on skin
care costs. A quarter of the study group received
assistance for household chores because of
psoriasis. For the patients who received
assistance, the estimated annual cost was
1,014 euro (SD 1,131).
DISCUSSION
There is little information concerning the costs
of psoriasis incurred by patients. In this study,
the co-payments for visits to hospital and for
medications and emollients comprised only a
minority of the total costs for a patient, while
Table 2 Average annual costs (euro) (standard deviation in parenthesis) for patients, receiving traditional systemic
medications (methotrexate, acitretin, cyclosporine), not receiving traditional systemic medications and to all patients
Cost item Receiving traditional systemic
medications (n5 85)
Not receiving traditional
systemic medications (n5 147)
All patients
(n5 232)
Medicine ? emollients 286 (199) 142** (186) 194 (202)
Visits to health care providersa 343 (574) 417 (467) 390 (509)
Time spent on skin care 1,199 (1,560) 807* (1,160) 950 (1,330)
Time spent on cleaning ? laundry 281 (743) 332 (935) 313 (869)
Assistance time 420 (932) 225* (653) 296 (771)
Total 2,530 (2,361) 1,924* (1,981) 2,145 (2,142)
** p\0.001, * p\0.05, otherwise non-signiﬁcant
a Includes all cost items of visits: charges, travel, travel time and visit time
Table 3 The composition of phototherapy costs (euro)
(standard deviation in parenthesis) (n = 83)
Cost items Cost
Travel costs 119 (151)
Travel time costs 181 (212)
Treatment time costs 66 (47)
Treatment charges 104 (50)
Total phototherapy cost 471 (387)
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travel costs and lost time were estimated to
contribute the majority of the costs to patients.
In a recent study in Spain [15], the relationship
of travel costs and time costs were similar from
the patients’ perspective.
Phototherapy has been estimated to be
costly for patients [2, 7, 8, 11]. In this study,
biologic therapy and phototherapy had almost
equal costs to patients. In studies in the US,
lower out-of-pocket costs for patients have been
estimated to have led to favoring biologic
therapies over phototherapy [16, 17]. This can
lead to higher total costs for the society of
psoriasis treatment as phototherapy has been
estimated to be the most cost-efficient, or one of
the most cost-efficient, treatment methods of
psoriasis [18–20]. However, travel costs and
travel time costs are rarely included in cost
estimations of psoriasis treatments [16, 19–21],
which may have led to underestimation of the
actual costs of phototherapy. The current
sample included all patients visiting the clinic
during 1 year. Thus, all types of phototherapy
patients can be assumed to be represented,
those in remission as well as those in active
treatment; and the costs were based on the
actual number of visits during the whole year.
In this study the indirect costs were
estimated to comprise the majority of costs of
phototherapy for the patients. Earlier studies
have estimated that travel costs account for
around two-thirds of the total costs of
phototherapy [22]. Time lost because of
phototherapy has been estimated to be around
110 min/treatment session [22] or take 33 h per
year [11]. It has been reported that, from the
perspective of patients, travel distance plays a
major role in treatment selection [23]. Loss of
time, whether working or leisure time, has value
to the patients, irrespective of the lost earnings.
In this study, the aim was to analyze the burden
of the disease to a patient, not to employers, or
the society as a whole. Thus, possible
productivity losses from absenteeism or
presenteeism were not included.
A recent study suggests that patients living
further away from UV-treatment facility have
lower dermatology life quality index (DLQI)
and suffer from lack of treatment [23]. The
current study indicated that patients living
further away from tertiary level hospital
receive less phototherapy, which may be due,
in part, to the decisions made by patients and
not just the decisions made by treatment
providers. Studies are required to determine if
patients living further away from service
provider suffer from under treatment. Home
phototherapy is rarely used in our study area
Table 4 Average annual costs (euro) of health care visits according to diagnosis (standard deviation in parenthesis)











Travel costs 49 (96) 125*** (191) 5 (11) 8 (18) 65 (119)
Travel time cost 77 (151) 178** (250) 11 (33) 16 (49) 103 (182)
Visit time cost 83 (296) 127 (301) 16 (44) 16 (25) 105 (300)
Charges 81 (90) 112 (121) 28 (88) 42 (76) 116 (120)
Total costs 291 (466) 543* (578) 61 (139) 82 (144) 390 (509)
*** p\0.001, ** p\0.005, * p\0.05, otherwise non-signiﬁcant
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although it seems that, at least for patients
living further away from the service provider, it
could increase treatment options.
In some earlier studies [16], medication costs
were estimated using average prices and average
weekly doses. This can be a source for potential
overestimates of medication costs as a
considerable proportion of psoriasis patients
do not necessarily use the medications as
prescribed [24]. In the study all medicine and
emollient costs were based on reimbursement
data of all purchases, irrespective of who had
prescribed the medications, which can be
expected to produce more reliable medication
cost estimates. Countries have varying social
security systems and reimbursement rates so
direct comparison between studies has been
considered problematic [7, 12, 25]. For example,
in this study setting, the cut-off level for
complete medicine cost reimbursement was
based on national policy. Thus, the
medication costs to patients in this study may
not be directly generalizable to other countries.
As in this study, earlier studies [8, 19] have
shown that patients receiving systemic
medications and/or phototherapy have higher
costs than those who were receiving only
topical treatment. Patients with systemic
medication or phototherapy also have been
estimated to have lower quality of life and a
higher likelihood of treatment failure than
other patients [19, 26]. In some studies,
patients receiving systemic medication or
phototherapy have been classified as having
severe psoriasis no matter what PASI scores they
had [11, 13]. On the other hand, patients
receiving systemic treatment or phototherapy
have been found to have lower PASI values than
other patients [8], possibly due to successful
control of psoriasis in patients receiving
adequate treatment. In the authors’ previous
work [27] topical therapies were most often
combined with other forms of treatment. More
severe psoriasis patients, who receive systemic
medications to control their symptoms, may
need more extensive self-care than those who
manage with less care, irrespective of PASI
values. These issues could explain why, in this
study, almost all costs were higher for patients
using systemic medications or phototherapy
even though the severity of psoriasis was
almost the same. However, in our study only
72 patients had PASI values in their medical
records, so analyses with PASI values are not as
generalizable as other results and should be
treated with more caution.
The primary provider of treatment for
patients with psoriasis varies between
countries [28]. In most studies patients have
been treated mainly by dermatologists [28, 29],
as in this study. In Finland, patients with well
managed and mild psoriasis are usually treated
by general practitioners, with referral to a
tertiary level dermatological clinic when
exacerbations occur. This may have led to
selection bias in the sample as only patients
from the dermatological clinic were included.
The current study corroborates earlier studies
[8, 11, 13, 30] that time devoted to skin care,
household chores and assistance for household
chores imposes a considerable burden to
patients with psoriasis. The estimates for time
used for skin care/topical treatment in previous
studies, have had a wide range from 4 min/daily
[11] to 57.5 min daily [8]. In this study, the use
of two different questions regarding skin care—
one estimating the time needed for skin care due
to psoriasis and one for the hypothetical time
needed for skin care if the patient did not have
psoriasis, may have produced more reliable
results on time needed due to psoriasis. The
study suggests that the time devoted to skin care
is a considerable burden, contributing to almost
half of the total costs for the patient. Laundry
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and cleaning seemed to have minor role in costs
for the patient, with the majority of patients
reporting negligible impact of psoriasis. For
those needing assistance, it may form a
considerable cost burden.
CONCLUSION
Information concerning the costs of psoriasis
from the perspective of patients is still limited.
In this study, the co-payments for visits to
hospital and for treatments were estimated to
play a minor role in the total costs for a patient,
with travel costs and lost time contributing
most of the costs. These indirect costs of
treatments should not be omitted in future
studies as they can be a significant factor when
choosing treatments, especially for the patients
with psoriasis.
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